We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
More and more pivotal clinical trials — typically Phase III studies — submitted in support of drug applications in Europe are being conducted outside of the region, a new report by the European Medicines Agency (EMA) finds. Read More